Basilico F, Sauerwein W, Pozzi F, Wittig A, Moss R, Mauri P L
Istituto Tecnologie Biomediche, via Fratelli Cervi, 93, Segrate, Milan, Italy.
J Mass Spectrom. 2005 Dec;40(12):1546-9. doi: 10.1002/jms.909.
Boron neutron capture therapy (BNCT) is a promising binary treatment for cancer. BNCT is based on the ability of the nonradioactive isotope (10)B to capture, with a very high probability, thermal neutrons. This nuclear reaction results in two particles (an alpha and a lithium nucleus). The particles have a high biological effectiveness, which is limited in tissue to approximately the diameter of one cell. If the reaction can be limited to a tumor cell, the physical characteristic opens up the possibility to selectively destroy cancer cells, while sparing the surrounding healthy tissue. Quality control of (10)B-containing compounds and their distribution at present are very important, and different analytical methods have been developed, such as time-of-flight secondary ion mass spectrometry (TOF-SIMS), electron energy loss spectrometry (EELS), prompt gamma analysis and inductively coupled plasma-optical emission spectrometry (ICP-OES). These methods allow the analyses of (10)B, but it is not possible to characterize the specific molecular compounds containing (10)B. For this reason, we propose a fast and quantitative method that permits the determination of closo-undecahydro-1-mercaptododecaborate (BSH) and (10)boron-phenylalanine (BPA) and their eventual metabolites. In particular, (10)B-containing compounds are detected by means of flow-injection electrospray tandem mass spectrometry (FI/ESI-MS/MS). This approach allows the identification of Boron compounds, BSH and BPA, using tandem mass spectrometry, and quantitative analysis is also possible (c.v. +/-4.7%; n = 5; linear range 10-10,000 ng/ml). Furthermore, (10)B-containing compounds were detected in actual biological sample (urine and plasma, diluted 10,000- and 1,000-fold, respectively) injecting a small volume (1 microl) of diluted samples.
硼中子俘获疗法（BNCT）是一种很有前景的癌症二元治疗方法。BNCT基于非放射性同位素硼-10（¹⁰B）以非常高的概率俘获热中子的能力。这种核反应产生两个粒子（一个α粒子和一个锂核）。这些粒子具有很高的生物有效性，在组织中的作用范围大约局限于一个细胞的直径。如果该反应能够局限于肿瘤细胞，这种物理特性就为选择性地破坏癌细胞同时 sparing the surrounding healthy tissue. Quality control of (10)B-containing compounds and their distribution at present are very important, and different analytical methods have been developed, such as time-of-flight secondary ion mass spectrometry (TOF-SIMS), electron energy loss spectrometry (EELS), prompt gamma analysis and inductively coupled plasma-optical emission spectrometry (ICP-OES). These methods allow the analyses of (10)B, but it is not possible to characterize the specific molecular compounds containing (10)B. For this reason, we propose a fast and quantitative method that permits the determination of closo-undecahydro-1-mercaptododecaborate (BSH) and (10)boron-phenylalanine (BPA) and their eventual metabolites. In particular, (10)B-containing compounds are detected by means of flow-injection electrospray tandem mass spectrometry (FI/ESI-MS/MS). This approach allows the identification of Boron compounds, BSH and BPA, using tandem mass spectrometry, and quantitative analysis is also possible (c.v. +/-4.7%; n = 5; linear range 10-10,000 ng/ml). Furthermore, (10)B-containing compounds were detected in actual biological sample (urine and plasma, diluted 10,000- and 1,000-fold, respectively) injecting a small volume (1 microl) of diluted samples.
保留周围健康组织创造了可能性。目前，含硼-10化合物的质量控制及其分布非常重要，并且已经开发了不同的分析方法，如飞行时间二次离子质谱法（TOF-SIMS）、电子能量损失谱法（EELS）、瞬发伽马分析和电感耦合等离子体发射光谱法（ICP-OES）。这些方法能够分析硼-10，但无法表征含硼-10的特定分子化合物。因此，我们提出了一种快速定量方法，可用于测定闭式十一氢-1-巯基十二硼酸盐（BSH）和硼-10-苯丙氨酸（BPA）及其最终代谢产物。特别是，通过流动注射电喷雾串联质谱法（FI/ESI-MS/MS）检测含硼-10的化合物。这种方法利用串联质谱法能够鉴定硼化合物、BSH和BPA，并且也可以进行定量分析（变异系数±4.7%；n = 五；线性范围10 - 10000 ng/ml）。此外，通过注入少量（1微升）稀释样品，在实际生物样品（尿液和血浆，分别稀释10000倍和1000倍）中检测到了含硼-10的化合物。 （你提供的英文原文中“sparing the surrounding healthy tissue.”后面内容似乎不完整且表述混乱，我按照现有内容尽量准确翻译了。）
